| Literature DB >> 17486454 |
R I Nicholson1, I R Hutcheson, H E Jones, S E Hiscox, M Giles, K M Taylor, J M W Gee.
Abstract
Growth factors provide powerful mitogenic and survival signals to breast cancer cells and it is therefore not surprising that they are able to subvert inhibitory responses to anti-hormonal drugs. In this review we discuss several mechanisms by which this may be achieved and expand our observations to encompass recently emerging anti-growth factor treatments. The information presented is underpinned by inhibitor studies that show the targeting of such mechanisms in advance of anti-hormone or anti-growth factor resistance development is able to substantially delay this event, thus pointing the way forward to intelligent combination therapies relevant to the future management of breast cancer.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17486454 DOI： 10.1007/s11154-007-9033-5
Source DB: PubMed Journal: Rev Endocr Metab Disord ISSN： 1389-9155 Impact factor: 6.514